Neumora Therapeutics, Inc. (NMRA) stock
NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.43−0.00 (-0.95%)
Close on Nov 13, 2026Market cap $80.59MP/E –Yield –
Neumora Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Neumora Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$211.23M. For fiscal 2025 it was -$241.16M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$241.16M | – |
| FY2024 | Dec 31, 2024 | -$263.46M | – |
| FY2023 | Dec 31, 2023 | -$252.10M | – |
| FY2022 | Dec 31, 2022 | -$135.87M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$42.19M | – |
| Q1 FY2026 | Mar 31, 2026 | -$52.86M | – |
| Q4 FY2025 | Dec 31, 2025 | -$58.48M | – |
| Q3 FY2025 | Sep 30, 2025 | -$57.70M | – |
| Q2 FY2025 | Jun 30, 2025 | -$54.04M | – |
| Q1 FY2025 | Mar 31, 2025 | -$70.94M | – |
| Q4 FY2024 | Dec 31, 2024 | -$62.92M | – |
| Q3 FY2024 | Sep 30, 2024 | -$76.65M | – |
| Q2 FY2024 | Jun 30, 2024 | -$63.82M | – |
| Q1 FY2024 | Mar 31, 2024 | -$60.07M | – |
| Q4 FY2023 | Dec 31, 2023 | -$114.00M | – |
| Q3 FY2023 | Sep 30, 2023 | -$56.86M | – |
| Q2 FY2023 | Jun 30, 2023 | -$42.06M | – |
| Q1 FY2023 | Mar 31, 2023 | -$39.17M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.72M | – |
| Q3 FY2022 | Sep 30, 2022 | -$30.60M | – |
See a number that looks wrong?